Skip to main content
. 2020 Jan 7;111(3):667–676. doi: 10.1093/ajcn/nqz333

TABLE 5.

ORs and 95% CIs for symptomatic progression of knee osteoarthritis according to quartiles of dietary pattern scores1

Model 12, 4 Model 23, 4
 Cases  Person-years OR (95% CI) P-value P-trend OR (95% CI) P-value P-trend
Western5
 Q1 594 1156 1.00 Ref <0.01 1.00 Ref <0.01
 Q2 609 1130 1.08 (0.92, 1.27) 0.32 1.06 (0.89, 1.25) 0.51
 Q3 608 1105 1.20 (1.02, 1.41) 0.03 1.15 (0.97, 1.37) 0.11
 Q4 629 1071 1.39 (1.18, 1.63) <0.01 1.26 (1.06, 1.50) <0.01
Prudent5
 Q1 618 1077 1.00 Ref <0.01 1.00 Ref <0.01
 Q2 611 1094 0.90 (0.77, 1.06) 0.20 0.90 (0.76, 1.07) 0.22
 Q3 614 1141 0.92 (0.78, 1.07) 0.27 0.90 (0.76, 1.06) 0.21
 Q4 597 1150 0.73 (0.62, 0.86) <0.01 0.71 (0.60, 0.84) <0.01
Western − prudent5
 Q1 591 1128 1.00 Ref <0.01 1.00 Ref <0.01
 Q2 617 1176 1.19 (1.01, 1.39) 0.03 1.19 (1.01, 1.41) 0.04
 Q3 613 1114 1.24 (1.06, 1.46) <0.01 1.22 (1.03, 1.44) 0.02
 Q4 619 1044 1.40 (1.19, 1.64) <0.01 1.29 (1.08, 1.53) <0.01
1

COX-2, cyclooxygenase-2; JSW, joint space width; KL, Kellgren–Lawrence; MSM, methylsulfonylmethane; NSAID, nonsteroidal anti-inflammatory drug; PASE, Physical Activity Scale for the Elderly.

2

Adjusted for age, sex, race (African American, white, other), baseline KL grade 1–3, injury/surgery (yes, no), depression (yes, no), narcotics for pain (yes, no), NSAID use (yes, no), SAMe (yes, no), MSM (yes, no), doxycycline (e.g., Vibra-Tabs, Doryx, Adoxa) (yes, no), COX-2 inhibitors (Bextra, Celebrex) (yes, no), and baseline PASE score and total energy intake (kcal/day, continuous) using a generalized linear mixed model.

3

Additionally adjusted for BMI (<25.0, 25.0–29.9, and ≥30 kg/m2), and weight change from baseline (continuous)

4

Additional adjustment for income, education, smoking, and alcohol did not significantly alter results.

5

Western pattern: Q1 is more healthy, Q4 is less healthy; Prudent pattern: Q1 is less healthy, Q4 is more healthy; Western − prudent pattern: Q1 is more healthy, Q4 is less healthy.